POPOVIČ, Mikuláš, Yiling LIU, Erika LATTOVÁ, Dean MANN, Sabrina CURRELI, Zbyněk ZDRÁHAL, Martin EDELMAN and Joseph BRYANT. In vivo and in vitro cell-based model of lung adenocarcinoma from patients with pleural effusion. Neoplasma. Slovenská akademie vied, 2021, vol. 68, No 3, p. 498-508. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2021_200906N953.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name In vivo and in vitro cell-based model of lung adenocarcinoma from patients with pleural effusion
Authors POPOVIČ, Mikuláš (840 United States of America), Yiling LIU (840 United States of America), Erika LATTOVÁ (703 Slovakia, guarantor, belonging to the institution), Dean MANN (840 United States of America), Sabrina CURRELI (840 United States of America), Zbyněk ZDRÁHAL (203 Czech Republic, belonging to the institution), Martin EDELMAN (840 United States of America) and Joseph BRYANT (840 United States of America).
Edition Neoplasma, Slovenská akademie vied, 2021, 0028-2685.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
WWW fulltext
Impact factor Impact factor: 3.409
RIV identification code RIV/00216224:14740/21:00123881
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.4149/neo_2021_200906N953
UT WoS 000662144000005
Keywords in English cell-based model of LAC; lung adenocarcinoma; growth pattern conversion; OCT-4; SOX-2; NANOG; pluripotent genes
Tags CF PROT, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 14/3/2022 13:28.
Abstract
Lung adenocarcinoma (LAC) is a common and aggressive form of lung cancer that is increasing in incidence among never smokers at a younger age. Current treatment of patients with LAC is insufficient and there is a need for identification of effective biomarkers and development of therapeutic targets. These demands require also unproved models for in vivo and in vitro experimentation. In this study, we describe the establishment of two LAC cell lines, named LuCa-3 and LuCa-6. Both were derived from pleural effusion (PE) cells of LAC patients (13 and 16) and readily propagated as tumor xenografts in immunodeficient mice. PE cells from the patient L6 exhibited also the capacity for in vitro growth and were cultured in two forms: (i) as a suspension growing cell population, labeled LuCa-6S, composed of non-clumping single cells; and (ii) as a monolayer-like culture, labeled LuCa-6A, exhibiting tight cell-to-cell and to culture surface adherence. Unique features of these two sublines and their cell clones are the capacity to convert from a non-clumping single-cell suspension into the adherent growth pattern and vice versa. Immunostaining of patients' tumor tissue xenografts and cultured subline cells displayed markers specific for the phenotype of human LAC. LuCa-6S and LuCa-6A cells did not reveal a noticeable disparity in quantitative growth characteristics. However, a number of differences were detected between these two cell populations manifested in detection or intensities of antigen expressions on the cell surface (CD133, SFTPC) and in the nucleus (TTF-1) including pluripotcnt (OCT-4, SOX-2, NANOG) genes in cancer stem-like cells (CSCs). Dissimilarities between these two sublines were also detected in N-glycan profiles and in the sensitivity to natural killer cells. Salient features of these subline cell populations are responsiveness to selective upregulation of the pluripotent genes in subsets of CSCs via conversion of their growth patterns and/or by using culture stem media with growth factors. The described in vivo/in vitro model enables broader experimental approaches in studies of lung adenocarcinoma.
Links
LM2018127, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 22/5/2024 18:02